Work

Abstract CT261: A Phase 1, open-label, dose-escalation study of selinexor plus ruxolitinib in patients with treatment-naïve myelofibrosis

Year: 2023

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2023-ct261

Authors: Haris Ali, Ashwin Kishtagari, Keri Maher, Sanjay Mohan, Karen Ansaldo, Xulong Wang, Kamal Chamoun, Josef T. Prchal, Srinivas K. Tantravahi

Institutions: City Of Hope National Medical Center, Vanderbilt University, Vanderbilt-Ingram Cancer Center, VCU Massey Comprehensive Cancer Center, Karyopharm Therapeutics (United States), University of Utah, Huntsman Cancer Institute

Language: English

Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4365512196

Cites:

Cited by: 3

Related to: 10